Lantern Pharma (NASDAQ: LTRN) has achieved a milestone with the European Patent Office issuing a notice of allowance for a composition of matter patent for LP-284, its clinical-stage drug candidate aimed at treating relapsed or refractory non-Hodgkin’s lymphoma. This patent, which is expected to grant exclusivity through 2039, complements existing intellectual property rights in the U.S. and Japan, facilitating the drug's global commercialization. LP-284, developed using Lantern’s RADR(R) AI platform, is currently in Phase 1 trials and has received Orphan Drug Designations for mantle cell lymphoma (MCL) and high-grade B-cell lymphoma (HGBL). Targeting a $4 billion global market, LP-284's development underscores the potential of AI in reducing the cost and time of drug discovery, offering hope for faster access to innovative cancer treatments.
The significance of this patent extends beyond Lantern Pharma, highlighting the growing role of artificial intelligence in transforming the pharmaceutical industry. By leveraging over 200 billion oncology-focused data points and a library of more than 200 machine learning algorithms, Lantern's RADR(R) platform exemplifies how technology can accelerate the development of life-saving drugs. The company's ability to advance drug programs from initial AI insights to clinical trials in just 2-3 years, at a fraction of the traditional cost, sets a new benchmark for efficiency in drug development. This achievement not only enhances Lantern's strategic partnership potential but also signals a shift towards more accessible and affordable cancer treatments worldwide.
